PERSISTER CONTROL BY LEVERAGING DORMANCY ASSOCIATED REDUCTION OF ANTIBIOTIC EFFLUX
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 30, 2025
app pub date -
Nov 15, 2022
filing date -
Nov 15, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A strategy for bacterial persister control using amphiphilic antibiotics that do not require active transport to penetrate bacterial membranes of persister cells. Persister cells have reduced drug efflux and accumulate more minocycline than normal cells, leading to effective killing of this dormant subpopulation upon wake-up. While dormancy is a well-known cause of antibiotic tolerance, it also provides an Achilles' heel for controlling persister cells by leveraging dormancy associated reduction of drug efflux.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully